Lieke Mitrov-Winkelmolen1, Marie-Christine W van Buul-Gast2, Dingeman J Swank3, Hans W P M Overdiek4, Ron H N van Schaik5, Daan J Touw6. 1. Department of Clinical Pharmacy, Ikazia Hospital and Maasstad Hospital, Rotterdam, The Netherlands. l.mitrov@ikazia.nl. 2. Department of clinical pharmacy, BovenIJ Hospital, Amsterdam, The Netherlands. 3. Dutch Obesity Clinic West, The Hague, The Netherlands. 4. Central Hospital Pharmacy, Medical Centre The Hague, The Hague, The Netherlands. 5. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands. 6. Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Data on the absorption of orally administered drugs following Roux-en-Y gastric bypass (RYGB) surgery in obese patients are limited and inconclusive. As it is difficult to predict changes in absorption, studies on frequently used drugs in this population are necessary. Acetylsalicylic acid (ASA) and omeprazole are two commonly prescribed drugs in obese patients. METHODS: In this repeated measures study, omeprazole and salicylic acid (SA) serum concentrations were measured before and after RYGB in 34 morbidly obese subjects. Time to maximum concentration (Tmax), lag time (Tlag), maximum concentration (Cmax), and area under the serum concentration versus time curve (AUC) were calculated for both drugs to determine possible differences in drug absorption after the procedure. RESULTS: For SA, Tmax significantly decreased after RYGB, while both Cmax and AUC0-24 significantly increased. For omeprazole, both Tmax and Tlag significantly decreased after RYGB, while Cmax significantly increased. Mean AUC0-12 significantly decreased post-surgery. The difference in AUC0-12 before and after surgery varied between subjects. CONCLUSIONS: Our study shows a faster absorption of both ASA and omeprazole after RYGB. The exposure to ASA is higher post-surgery, but the standard dose of 80 mg does not need to be modified, considering its range in effective dose. The exposure to omeprazole is, on average, decreased after surgery. Clinicians should be aware to increase the dose of omeprazole if symptoms suggest inadequate response.
BACKGROUND: Data on the absorption of orally administered drugs following Roux-en-Y gastric bypass (RYGB) surgery in obesepatients are limited and inconclusive. As it is difficult to predict changes in absorption, studies on frequently used drugs in this population are necessary. Acetylsalicylic acid (ASA) and omeprazole are two commonly prescribed drugs in obesepatients. METHODS: In this repeated measures study, omeprazole and salicylic acid (SA) serum concentrations were measured before and after RYGB in 34 morbidly obese subjects. Time to maximum concentration (Tmax), lag time (Tlag), maximum concentration (Cmax), and area under the serum concentration versus time curve (AUC) were calculated for both drugs to determine possible differences in drug absorption after the procedure. RESULTS: For SA, Tmax significantly decreased after RYGB, while both Cmax and AUC0-24 significantly increased. For omeprazole, both Tmax and Tlag significantly decreased after RYGB, while Cmax significantly increased. Mean AUC0-12 significantly decreased post-surgery. The difference in AUC0-12 before and after surgery varied between subjects. CONCLUSIONS: Our study shows a faster absorption of both ASA and omeprazole after RYGB. The exposure to ASA is higher post-surgery, but the standard dose of 80 mg does not need to be modified, considering its range in effective dose. The exposure to omeprazole is, on average, decreased after surgery. Clinicians should be aware to increase the dose of omeprazole if symptoms suggest inadequate response.
Entities:
Keywords:
Acetylsalicylic acid (Aspirin); Drug absorption; Omeprazole; Roux-en-Y gastric bypass
Authors: James L Roerig; Kristine Steffen; Cheryl Zimmerman; James E Mitchell; Ross D Crosby; Li Cao Journal: Surg Obes Relat Dis Date: 2010-12-15 Impact factor: 4.734
Authors: Sweta Tandra; Naga Chalasani; David R Jones; Samer Mattar; Stephen D Hall; Raj Vuppalanchi Journal: Ann Surg Date: 2013-08 Impact factor: 12.969
Authors: Jan Peter Yska; Susanne van der Linde; Véronique V Tapper; Jan A Apers; Marloes Emous; Erik R Totté; Bob Wilffert; Eric N van Roon Journal: Obes Surg Date: 2013-06 Impact factor: 4.129
Authors: I B Skottheim; K Stormark; H Christensen; G S Jakobsen; J Hjelmesaeth; T Jenssen; J L E Reubsaet; R Sandbu; A Asberg Journal: Clin Pharmacol Ther Date: 2009-06-03 Impact factor: 6.875
Authors: Antonio Portolés-Pérez; Ana Belén Rivas Paterna; Andrés Sánchez Pernaute; Antonio José Torres García; Carmen Moreno Lopera; Luis M Chicharro; Fernando Bandrés; Amanda López-Picado; Miguel A Rubio; Emilio Vargas Castrillón Journal: Obes Facts Date: 2022-01-03 Impact factor: 4.807
Authors: Jan Peter Yska; Jacquelien T M Wanders; Blessing Odigie; Jan A Apers; Marloes Emous; Erik R E Totté; E Christiaan Boerma; Froukje L Ubels; Herman J Woerdenbag; Henderik W Frijlink; Bob Wilffert; Eric N van Roon Journal: Eur J Hosp Pharm Date: 2019-02-15
Authors: Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe Journal: Br J Clin Pharmacol Date: 2021-06-03 Impact factor: 3.716
Authors: Philip Carlo Angeles; Ida Robertsen; Lars Thomas Seeberg; Veronica Krogstad; Julie Skattebu; Rune Sandbu; Anders Åsberg; Jøran Hjelmesaeth Journal: Obes Rev Date: 2019-06-24 Impact factor: 9.213
Authors: Kine Eide Kvitne; Veronica Krogstad; Christine Wegler; Line Kristin Johnson; Marianne K Kringen; Markus Herberg Hovd; Jens K Hertel; Maria Heijer; Rune Sandbu; Eva Skovlund; Per Artursson; Cecilia Karlsson; Shalini Andersson; Tommy B Andersson; Jøran Hjelmesaeth; Anders Åsberg; Rasmus Jansson-Löfmark; Hege Christensen; Ida Robertsen Journal: Br J Clin Pharmacol Date: 2022-04-25 Impact factor: 3.716